Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | BTK | Q06187 | 1/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.56 |
| ▸ | HPGDS | O60760 | 2/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | PNP | P00491 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30060621 | 1.00 | KMT2A (0.58) | KMT2ABTKNPY5RHPGDSCYP2A6 | |
| SCHEMBL1133436 | 0.81 | GAA (0.50) | KMT2ABTKNPY5RHPGDMAPT | |
| SCHEMBL7454459 | 0.77 | PDE3B (0.50) | NPY5RHPGDSHPGDMAPTALDH1A1 | |
| SCHEMBL6889908 | 0.75 | NPY5R (0.55) | BTKNPY5RHPGDSHPGDMAPT | |
| SCHEMBL17810406 | 0.73 | NPY5R (0.62) | BTKNPY5RHPGDSCYP2A6ALDH1A1 | |
| SCHEMBL30814200 | 0.73 | NOTUM (0.60) | KMT2ABTKNPY5RCYP2A6ALDH1A1 | |
| SCHEMBL20752581 | 0.73 | NPY5R (0.62) | KMT2ANPY5RHPGDSCYP2A6 | |
| SCHEMBL30176417 | 0.73 | NOTUM (0.60) | KMT2ABTKNPY5RCYP2A6ALDH1A1 | |
| SCHEMBL1129657 | 0.72 | ALDH1A1 (0.39) | KMT2ABTKHPGDALDH1A1 | |
| SCHEMBL3829517 | 0.72 | HRH1 (0.51) | NPY5RALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014128213-A1 | COMPOUNDS FOR USE IN INHIBITING HIV CAPSID ASSEMBLY | Ruprecht-Karls-Universität Heidelberg (DE) | 2014-08-28 | — | — | WO | disclosed |
| WO-2014128213-A1 | COMPOUNDS FOR USE IN INHIBITING HIV CAPSID ASSEMBLY | Ruprecht-Karls-Universität Heidelberg (DE) | 2014-08-28 | — | — | WO | disclosed |
| EP-2769722-A1 | Compounds for use in inhibiting HIV capsid assembly | Ruprecht-Karls-Universität Heidelberg (DE) | 2014-08-27 | — | — | EP | disclosed |
| EP-2769722-A1 | Compounds for use in inhibiting HIV capsid assembly | Ruprecht-Karls-Universität Heidelberg (DE) | 2014-08-27 | — | — | EP | disclosed |
| US-6936600-B2 | Sorbitol dehrydrogenase inhibitors | PFIZER INC (US) | 2005-08-30 | — | — | US | disclosed |
| US-6869943-B2 | Sorbitol dehydrogenase inhibitors | PFIZER INC (US) | 2005-03-22 | — | — | US | disclosed |
| US-20050020578-A1 | Sorbitol dehydrogenase inhibitors | PFIZER INC. | 2005-01-27 | — | — | US | disclosed |
| US-20040077671-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2004-04-22 | — | — | US | disclosed |
| US-6660740-B1 | Sorbitol dehydrogenase inhibitors | PFIZER INC | 2003-12-09 | — | — | US | disclosed |
| US-6602875-B2 | Sorbitol dehydrogenase inhibitors | PFIZER INC | 2003-08-05 | — | — | US | disclosed |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2003-04-03 | — | — | US | disclosed |
| US-6414149-B1 | TREATING DIABETES, TREATING OR PREVENTING DIABETIC COMPLICATIONS | PFIZER INC. | 2002-07-02 | — | — | US | disclosed |
| CN-1351497-A | Aminopyrimidines as sorbitol dehydrogenase inhibitors | PFIZER PROD INC (US) | 2002-05-29 | — | — | CN | disclosed |
| EP-1185275-A1 | AMINOPYRIMIDINES AS SORBITOL DEHYDROGENASE INHIBITORS | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000059510-A1 | AMINOPYRIMIDINES AS SORBITOL DEHYDROGENASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020578-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | KMT2A 3908/4885BTK 4676/4885NPY5R 3506/4885 |
| US-20040077671-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | KMT2A 4011/4885BTK 4705/4885NPY5R 3325/4885 |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | KMT2A 4011/4885BTK 4705/4885NPY5R 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.